Jeenah Moon/Getty Images News Pfizer ( NYSE: PFE ) announced Tuesday that its Chief Scientific Officer and President of Research & Development (R&D), Mikael Dolsten, will leave the company after more than 15 years of service. The New York-based pharma giant said it is launching a months-long external search process to identify a new Chief Scientific Officer, an initiative expected to last until early next year. “Dr.
Dolsten will assist in this search and continue to serve in his current position until his successor is in place and any necessary transition is complete,” the company said. Dolsten joined Pfizer ( PFE ) as the President of Global R&D with the company’s Wyeth acquisition in 2009. He was part of Pfizer ( PFE ) as the company went on to secure approvals for more than 35 drugs and vaccines, including its most notable product, the Comirnaty COVID-19 shot, developed with German drugmaker BioNTech ( BNTX ).
More on Pfizer Pfizer: The Inflection Point Is Here Pfizer: It Could Be A Bargain Wall Street Lunch: Pfizer Looks To Take Next Step In Weight-Loss Drugs Executive reshuffles: NIO, Pfizer and Spirit Airlines in focus COVID infections could be seeing a summer surge based on CDC data.
